Table 2.
EGFR expression and clinical characteristics of the study population
| EGFR extent | P value | EGFR intensity | P value | |||
| Parameters | <25% | ≥25% | Negative to moderate | Strong | ||
| Age (y) | ||||||
| ≤64 | 26 (45.6)a | 13 (65) | 36 (50.7) | 3 (50) | ||
| >64 | 31 (54.4) | 7 (35) | 0.14 | 35 (49.3) | 3 (50) | 0.97 |
| Gender | ||||||
| Male | 38 (66.7) | 13 (65) | 47 (66.2) | 4 (66.7) | ||
| Female | 19 (33.3) | 7 (35) | 0.89 | 24 (33.8) | 2 (33.3) | 0.98 |
| Stage groupb | ||||||
| II | 43 (75.4) | 15 (75) | 54 (76.1) | 4 (66.7) | ||
| III | 14 (24.6) | 5 (25) | 0.97 | 17 (23.9) | 2 (33.3) | 0.61 |
| Tumor location | ||||||
| Lower third | 39 (68.4) | 13 (65) | 46 (64.8) | 6 (100) | ||
| Middle third | 12 (21.1) | 5 (25) | 17 (23.9) | - | ||
| Upper third | 6 (10.5) | 2 (10) | 0.96 | 8 (11.3) | - | 0.21 |
| Preoperative | ||||||
| RT-CTc | 8 (14) | 5 (25) | 0.26 | 11 (15.5) | 2 (33.3) | 0.26 |
| Preoperative RT | ||||||
| 44 Gy | 40 (70.2) | 12 (60) | 48 (67.6) | 4 (66.7) | ||
| 60 Gy | 17 (28.8) | 8 (40) | 0.40 | 23 (32.4) | 2 (33.3) | 0.96 |
| Type of surgeryd | ||||||
| AP | 46 (80.7) | 17 (85) | 58 (81.7) | 5 (83.3) | ||
| LAR | 11 (19.3) | 3 (15) | 0.67 | 13 (18.3) | 1 (16.7) | 0.92 |
| Resection | ||||||
| Margins | ||||||
| - | 52 (93) | 17 (85) | 63 (90) | 6 (100) | ||
| + | 4 (7) | 3 (15) | 0.30 | 7 (10) | - | 0.41 |
| Adjuvant | ||||||
| chemotherapy | 16 (28.1) | 9 (45) | 0.16 | 24 (33.8) | 1 (16.7) | 0.39 |
aData are presented as number of patients, with the percentage in parentheses.
bAccording to AJCC (American Joint Committee on Cancer) 1997.
cPreoperative chemo-radiotherapy.
dAP, abdominoperineal excision; LAR, low anterior resection